The programmed death receptor-1 (PD-1) blocking antibody pembrolizumab ( Keytruda – Merck), which has been available in an IV formulation since 2014 for treatment of various malignancies, has now been…
Med Lett Drugs Ther. 2025 Nov 10; 67(1741):e184 doi:10.58347/tml.2025.1741f
The programmed death receptor-1 (PD-1) blocking antibody pembrolizumab ( Keytruda – Merck), which has been available in an IV formulation since 2014 for treatment of various malignancies, has now been approved in a subcutaneous formulation as Keytruda Qlex . Keytruda Qlex is the first immune checkpoint inhibitor to become available in the US that can be administered subcutaneously. It has been approved for 38 of the 41 solid tumor indications that Keytruda is approved for. Keytruda's patent exclusivity expires in 2028.
The FDA has approved Inlexzo , a gemcitabine intravesical system, for treatment of Bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ , with or…
Med Lett Drugs Ther. 2025 Oct 27; 67(1740):e176-7 doi:10.58347/tml.2025.1740c
The FDA has approved Inlexzo , a gemcitabine intravesical system, for treatment of Bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ , with or without papillary tumors. The Inlexzo system is placed into the bladder to deliver gemcitabine for 3 weeks.
Cosibelimab ( Unloxcyt – Checkpoint Therapeutics), a programmed death ligand-1 (PD-L1) blocking antibody, has been approved by the FDA for treatment of locally advanced or metastatic cutaneous squamous cell…
Med Lett Drugs Ther. 2025 Feb 17; 67(1722):e32-3 doi:10.58347/tml.2025.1722g
Cosibelimab ( Unloxcyt – Checkpoint Therapeutics), a programmed death ligand-1 (PD-L1) blocking antibody, has been approved by the FDA for treatment of locally advanced or metastatic cutaneous squamous cell carcinoma in adults who are not candidates for curative surgery or radiation. It is the first PD-L1 inhibitor to be approved in the US for this indication. The PD-1 inhibitors pembrolizumab (Keytruda) and cemiplimab (Libtayo) are also approved for treatment of cutaneous squamous cell carcinoma.
Nogapendekin alfa inbakicept-pmln ( Anktiva – ImmunityBio), a first-in-class interleukin-15 (IL15) receptor agonist, has been approved by the FDA for use with Bacillus Calmette-Guérin (BCG) for treatment of…
Med Lett Drugs Ther. 2024 Jun 24; 66(1705):e105-6 doi:10.58347/tml.2024.1705e
Nogapendekin alfa inbakicept-pmln ( Anktiva – ImmunityBio), a first-in-class interleukin-15 (IL15) receptor agonist, has been approved by the FDA for use with Bacillus Calmette-Guérin (BCG) for treatment of patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary tumors. Such patients generally undergo bladder tumor resection, followed by intravesical BCG treatment, but treatment failure and cancer recurrence are common. The adenoviral vector-based intravesical gene therapy nadofaragene firadenovec-vncg (Adstiladrin) and the immune checkpoint inhibitor pembrolizumab (Keytruda) are also approved for the same indication.
Erdafitinib (Balversa – Janssen), an oral kinase inhibitor, has received full approval from the FDA for treatment of locally advanced or metastatic urothelial carcinoma in adults with susceptible FGFR3…
Med Lett Drugs Ther. 2024 May 13; 66(1702):e83-4 doi:10.58347/tml.2024.1702g
Erdafitinib (Balversa – Janssen), an oral kinase inhibitor, has received full approval from the FDA for treatment of locally advanced or metastatic urothelial carcinoma in adults with susceptible FGFR3 (fibroblast growth factor receptor) genetic alterations who had disease progression on or after at least one prior line of systemic therapy. It is not recommended for use in patients who are eligible for but have not received prior PD-1 (programmed death receptor-1) or PD-L1 (programmed death-ligand 1) inhibitor therapy. Erdafitinib is the first oral FGFR kinase inhibitor to be approved in the US.
The FDA has approved tislelizumab ( Tevimbra – BeiGene), a programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic esophageal squamous cell cancer in adults who…
Med Lett Drugs Ther. 2024 May 13; 66(1702):e85-6 doi:10.58347/tml.2024.1702h
The FDA has approved tislelizumab ( Tevimbra – BeiGene), a programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic esophageal squamous cell cancer in adults who received prior systemic chemotherapy that did not include a programmed death ligand-1 (PD-L1) inhibitor.
Lifileucel ( Amtagvi – Iovance), a tumor-derived autologous T-cell immunotherapy, has received accelerated approval from the FDA for one-time treatment of adults with unresectable or metastatic melanoma…
Med Lett Drugs Ther. 2024 Apr 29; 66(1701):e77-8 doi:10.58347/tml.2024.1701h
Lifileucel ( Amtagvi – Iovance), a tumor-derived autologous T-cell immunotherapy, has received accelerated approval from the FDA for one-time treatment of adults with unresectable or metastatic melanoma previously treated with a programmed death receptor-1 (PD-1) inhibitor, and if BRAF V600 mutation-positive, a BRAF inhibitor with or without a mitogen-activated kinase (MEK) inhibitor. It is the first cellular therapy to be approved for use in solid tumors. Accelerated approval of lifileucel was based on objective response rates.
Enfortumab vedotin-ejfv ( Padcev – Astellas), a nectin-4-directed antibody and microtubule inhibitor conjugate, has received accelerated approval from the FDA for use with the immune checkpoint inhibitor…
Med Lett Drugs Ther. 2023 May 22; 65(1677):e91-2 doi:10.58347/tml.2023.1677g
Enfortumab vedotin-ejfv ( Padcev – Astellas), a nectin-4-directed antibody and microtubule inhibitor conjugate, has received accelerated approval from the FDA for use with the immune checkpoint inhibitor pembrolizumab (Keytruda) for treatment of locally advanced or metastatic urothelial cancer in adults who are ineligible for cisplatin-containing chemotherapy. Accelerated approval was based on tumor response rates and the durability of response.
Retifanlimab-dlwr ( Zynyz – Incyte), a programmed death receptor-1 (PD-1) blocking antibody, has received accelerated approval from the FDA for treatment of metastatic or recurrent locally advanced Merkel…
Med Lett Drugs Ther. 2023 Apr 17; 65(1674):e73-4 doi:10.58347/tml.2023.1674h
Retifanlimab-dlwr ( Zynyz – Incyte), a programmed death receptor-1 (PD-1) blocking antibody, has received accelerated approval from the FDA for treatment of metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) in adults. Accelerated approval of the drug was based on the response rate and duration of response. Retifanlimab is the third drug to be approved in the US for treatment of MCC; pembrolizumab (Keytruda) , a PD-1 blocking antibody, is approved for the same indication as retifanlimab in patients ≥12 years old and avelumab (Bavencio) , a programmed death ligand-1 (PD-L1) blocking antibody, is approved for treatment of metastatic MCC in patients ≥12 years old.
Nadofaragene firadenovec-vncg ( Adstiladrin – Ferring), an adenoviral vector-based gene therapy, has been approved by the FDA for treatment of adults with high-risk Bacillus Calmette-Guérin…
Med Lett Drugs Ther. 2023 Mar 6; 65(1671):e40-1 doi:10.58347/tml.2023.1671e
Nadofaragene firadenovec-vncg ( Adstiladrin – Ferring), an adenoviral vector-based gene therapy, has been approved by the FDA for treatment of adults with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary tumors. It is the first adenoviral vector-based gene therapy to be approved in the US for this indication. The immune checkpoint inhibitor pembrolizumab (Keytruda) was approved for the same indication in 2021.
Opdualag (BMS), a fixed-dose combination of two immune checkpoint inhibitors — nivolumab (Opdivo) , a programmed death receptor-1 (PD-1) inhibitor, and relatlimab-rmbw, a lymphocyte-activation gene-3 (LAG-3)…
Med Lett Drugs Ther. 2023 Jan 23; 65(1668):e19-20 doi:10.58347/tml.2023.1668g
Opdualag (BMS), a fixed-dose combination of two immune checkpoint inhibitors — nivolumab (Opdivo) , a programmed death receptor-1 (PD-1) inhibitor, and relatlimab-rmbw, a lymphocyte-activation gene-3 (LAG-3) blocking antibody — has been approved by the FDA for treatment of unresectable or metastatic melanoma in patients ≥12 years old. Relatlimab, which is only available in combination with nivolumab, is the first LAG-3 blocking antibody to become available in the US. Immune checkpoint inhibitors, including the anti-CTLA-4 antibody ipilimumab (Yervoy) and the PD-1 inhibitors nivolumab and pembrolizumab (Keytruda) , have been available for several years for treatment of melanoma.
The immune checkpoint inhibitor pembrolizumab ( Keytruda – Merck), a programmed death receptor-1 (PD-1) inhibitor, has been granted accelerated approval by the FDA for use in adults and children who have…
The FDA has approved avelumab ( Bavencio – EMD Serono) and durvalumab ( Imfinzi – AstraZeneca), two new immune check point inhibitors, and pembrolizumab ( Keytruda – Merck), a checkpoint inhibitor that…
Med Lett Drugs Ther. 2017 Dec 4; 59(1535):e202-3
The FDA has approved avelumab ( Bavencio – EMD Serono) and durvalumab ( Imfinzi – AstraZeneca), two new immune check point inhibitors, and pembrolizumab ( Keytruda – Merck), a checkpoint inhibitor that has been available in the US since 2014, for treatment of locally advanced or metastatic bladder cancer. Nivolumab (Opdivo) and atezolizumab (Tecentriq) were approved earlier for this indication.
The FDA has approved the fully-human programmed death ligand 1 (PD-L1) blocking antibody avelumab ( Bavencio – EMD Serono/Pfizer) for treatment of metastatic Merkel cell carcinoma (MCC) in patients ≥12…
The FDA has approved the immune checkpoint inhibitor atezolizumab ( Tecentriq – Genentech) for treatment of locally advanced or metastatic urothelial carcinoma and metastatic non-small cell lung cancer…
Med Lett Drugs Ther. 2017 Feb 27; 59(1515):e40-1
The FDA has approved the immune checkpoint inhibitor atezolizumab ( Tecentriq – Genentech) for treatment of locally advanced or metastatic urothelial carcinoma and metastatic non-small cell lung cancer (NSCLC) that have progressed during or following platinum-based chemotherapy. Atezolizumab is the first programmed death-ligand 1 (PD-L1) blocking antibody to become available in the US. Two other immune checkpoint inhibitors, the programmed death receptor-1 (PD-1) inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda) , are also approved for treatment of metastatic NSCLC, and nivolumab is also approved for second-line treatment of locally advanced or metastatic urothelial carcinoma.
The FDA has approved the immune checkpoint inhibitor pembrolizumab ( Keytruda – Merck), a programmed death receptor-1 (PD-1) inhibitor, for first-line treatment of patients with metastatic non-small cell…
Med Lett Drugs Ther. 2017 Jan 30; 59(1513):22-3
The FDA has approved the immune checkpoint inhibitor pembrolizumab ( Keytruda – Merck), a programmed death receptor-1 (PD-1) inhibitor, for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) that highly expresses programmed death-ligand 1 (PD-L1) and has no epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) translocations. About 25% of patients with advanced NSCLC have tumors with high levels of PD-L1 expression (PD-L1 expressed on ≥50% of tumor cells). Pembrolizumab was approved earlier for treatment of metastatic NSCLC with PD-L1 expression ≥1% that progressed on or after platinum-based chemotherapy.
The FDA has approved the mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor cobimetinib ( Cotellic – Genentech) for use in combination with the BRAF kinase inhibitor vemurafenib…
Med Lett Drugs Ther. 2016 Mar 28; 58(1491):43-4
The FDA has approved the mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor cobimetinib ( Cotellic – Genentech) for use in combination with the BRAF kinase inhibitor vemurafenib (Zelboraf) for treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
The FDA has approved nivolumab ( Opdivo – BMS), an IV programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic melanoma that has progressed following treatment with…
Med Lett Drugs Ther. 2015 Jun 8; 57(1470):85-7
The FDA has approved nivolumab ( Opdivo – BMS), an IV programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic melanoma that has progressed following treatment with ipilimumab (and a BRAF inhibitor in patients who are BRAF V600 mutation positive) and for treatment of metastatic squamous non-small cell lung cancer (NSCLC) that has progressed on or after platinum-based chemotherapy. It is the second PD-1 inhibitor to be marketed in the US after pembrolizumab (Keytruda) , and the first to be approved for treatment of NSCLC.
The FDA has approved pembrolizumab ( Keytruda – Merck), a human programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic melanoma that has progressed following…
Med Lett Drugs Ther. 2014 Nov 10; 56(1455):e114-5
The FDA has approved pembrolizumab ( Keytruda – Merck), a human programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic melanoma that has progressed following treatment with ipilimumab (Yervoy) and, if the patient is BRAF V600 mutation positive, a BRAF inhibitor. It is the fi rst PD-1 inhibitor to be marketed in the US. Nivolumab, another PD-1 inhibitor, is available in Japan. Pembrolizumab was previously known as lambrolizumab.